{"classes":[{"categories":[{"measurements":[{"comment":"Too few events to estimate the upper 80% confidence interval (CI)","groupId":"OG000","lowerLimit":"3.5","upperLimit":"NA","value":"74.9"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG001","lowerLimit":"0.7","upperLimit":"NA","value":"1.6"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG002","lowerLimit":"0.8","upperLimit":"NA","value":"1.4"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG003","lowerLimit":"2.1","upperLimit":"NA","value":"3.7"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG004","lowerLimit":"11.6","upperLimit":"NA","value":"14.0"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"6.0","value":"2.3"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG006","lowerLimit":"0.7","upperLimit":"NA","value":"2.8"},{"groupId":"OG007","lowerLimit":"0.7","upperLimit":"12.3","value":"7.2"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG008","lowerLimit":"0.3","upperLimit":"NA","value":"4.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"2"}],"units":"Participants"}],"description":"TTP was the time from the first administration of AMG 224 to the first objective assessment of disease progression as per IMWG-URC or deaths or if applicable date of censoring. The median TTP was estimated using the Kaplan-Meier method","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \\[MTD\\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG007","title":"Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment"},{"description":"Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG008","title":"Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment"}],"paramType":"MEDIAN","populationDescription":"The safety analysis set included all participants who received at least 1 dose of AMG 224.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1 to up to the end of study visit; up to approximately 6 years","title":"Time To Progression (TTP) According to IMWG-URC","type":"SECONDARY","unitOfMeasure":"months"}